Olfactomedin 4 (OLFM4) expression is associated with nodal metastases in esophageal adenocarcinoma

Lucia Suzuki¹, Fiebo J. C. ten Kate¹, Annieke W. Gotink², Hans Stoop¹, Michail Doukas¹, Daan Nieboer³, Manon C. W. Spaander², Jan J. B. van Lanschot⁴, Bas P. L. van Wijnhoven⁴, Arjun D. Koch², Marco J. Bruno², Leendert H. J. Looijenga¹*¹, Katharina Biermann¹*

¹ Department of Pathology, Erasmus MC University Medical Center Rotterdam, Cancer Institute, Rotterdam, The Netherlands, 2 Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Cancer Institute, Rotterdam, The Netherlands, 3 Department of Public Health, Erasmus MC University Medical Center Rotterdam, Cancer Institute, Rotterdam, The Netherlands, 4 Department of Surgery, Erasmus MC University Medical Center Rotterdam, Cancer Institute, Rotterdam, The Netherlands

Current address: Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
* k.biermann@erasmusmc.nl

Abstract

To date no informative biomarkers exist to accurately predict presence of lymph node metastases (LNM) in esophageal adenocarcinoma (EAC). We studied the discriminative value of Olfactomedin 4 (OLFM4), an intestinal stem cell marker, in EAC. Patients who had undergone esophagectomy as single treatment modality for both advanced (pT2-4) and early (pT1b) adenocarcinoma of the esophagus or gastro-esophageal junction were selected for this study from an institutional database (Erasmus MC University Medical Center, Rotterdam, The Netherlands). Surgical resection specimens of 196 advanced and 44 early EAC were examined. OLFM4 expression was studied by immunohistochemistry and categorized as low (<30%) or high (≥30%) expression. Low OLFM4 was associated with poor differentiation grade in both advanced (60% vs. 34.8%, p = 0.001) and early EAC (39.1% vs. 9.5%, p = 0.023). LNM were present in 161 (82.1%) of advanced and 9 (20.5%) of early EAC respectively. Low OLFM4 was independently associated with the presence of LNM in advanced EAC in multivariable analysis (OR 2.7; 95% CI, 1.16–6.41; p = 0.022), but not in early EAC (OR 2.1; 95% CI, 0.46–9.84; p = 0.338). However, the difference in association with LNM between advanced (OR 2.7; 95% CI, 1.16–6.41; p = 0.022) and early (OR 2.3; 95% CI, 0.47–11.13; p = 0.302) EAC was non-significant (p = 0.844), suggesting that the lack of significance in early EAC is due to the small number of patients in this group. OLFM4 was not of significance for the disease free and overall survival. Overall, low expression of intestinal stem cell marker OLFM4 was associated with the presence of LNM. Our study suggests that OLFM4 could be an informative marker with the potential to improve preoperative assessment in patients with EAC. Further studies are needed to confirm the value of OLFM4 as a biomarker for LNM.
Competing interests: The authors have declared that no competing interests exist.

Abbreviations: BE, Barrett’s esophagus; CI, confidence interval; DFS, disease free survival; EAC, esophageal adenocarcinoma; ESCC, esophageal squamous cell carcinoma; FFPE, formalin-fixed paraffin-embedded; G-CSF, granulocyte colony stimulating factor; HGD, high grade dysplasia; HR, hazard ratio; IHC, immunohistochemistry; LNM, lymph node metastasis; LGR5, leucin rich repeat containing G protein coupled receptor 5; nCRT, neo-adjuvant chemoradiation therapy; NDBE, non-dysplastic Barrett’s esophagus; OLFM4, Olfactomedin 4; OR, odds ratio; OS, overall survival; pT0, pathologic examination shows no regional lymph node metastasis; pT1a, pathologic examination shows tumor invading the lamina propria; pT1b, pathologic examination shows tumor invading the submucosa; pT2, pathologic examination shows tumor invading muscularis propria and/or adventitia; pT3, pathologic examination shows tumor invading neighboring organs and/or those dying from surgical complications (survival < 1 month) were excluded as well as patients that received (neo-)adjuvant chemoradiation therapy ((n)CRT). In addition,
all patients with early (pT1b) EAC, treated between 1992–2014 at the Erasmus MC, were inves-
tigated. These patients were treated by either primary esophagectomy or endoscopic resection
followed by esophagectomy because of poor prognostic criteria found in the endoscopic resec-
tion specimen. To increase patient numbers in the early EAC group, patients with early EAC
and less than 12 pathologically examined lymph nodes, but available follow-up for more than
60 months were also included.

Clinical and pathological data had been prospectively collected, including age at surgery,
sex, tumor location and size, surgical technique, resection margin status, differentiation grade,
presence (pN-/ pN+) and number (pN0-3) of pathologically confirmed lymph node metastasis
and disease free survival (DFS) and overall survival (OS). Resection margin positivity was
defined as presence of tumor cells in the (inked) resection margin (definitions according to
the College of American Pathologists (CAP)) [26]. Recurrence was defined as either locoregion-
al or distant during follow-up, which was either a clinical diagnosis and sometimes patholog-
ically confirmed. DFS was defined as time between the date of surgery and first occurrence of
disease progression. OS was defined as time between surgery and death. Patients lost to follow-
up were censored at the time of the last visit to the outpatient clinics. The TNM system accord-
ing to the UICC seventh edition was used for pathological grading and staging [4]. However,
corresponding to the eighth edition, which shows no changes in the definitions of the T, N,
and M categories, only carcinomas with their epicentre within the proximal 2 cm of the cardia
(Siewert types I and II tumors) were included [27].

**Specimen characteristics**

The hematoxylin-eosin stained slides and tissue blocks were retrieved from the archives of the
Department of Pathology at the Erasmus MC University Medical Center and re-assessed for
tumor staging, grading and additional immunohistochemical staining (IHC) for OLFM4.
From the most representative slide with deepest tumor invasion, the FFPE block was selected
and 4 μm thick sections were cut from this block. OLFM4 (clone DIE4M, Cell Signalling ref.
14369) staining was performed using an automated immunostainer (BenchMark Ultra, Vent-
tana Medical Systems, Roche, Tuscon, AZ, USA). In brief, deparaffinization according to
BenchMark Ultra protocol and antigen retrieval by CC1 antigen retrieval solution (64 min, ref.
950–124, Ventana Medical Systems) were performed. Tissues were incubated with the primary
antibody OLFM4 (32 min, dilution 1:400). Detection was performed with UltraView-DAB
(ref. 760–500, Ventana Medical Systems) and amplification with Amplification Kit (ref. 760–
080 Ventana Medical Systems). Next, the slides were counterstained with hematoxylin (ref:
790–2208, Ventana Medical Systems) and coverslipped. Each slide contained normal colon tis-
sue as a positive control. Furthermore, normal tissue surrounding the tumor was evaluated for
its physiological expression of OLFM4 and to assess background staining. OLFM4 expression
was scored based on the percentage of tumor cells with cytoplasmic OLFM4 staining. In addi-
tion, the H-score based on predominant staining intensity (no / weak/ moderate/ strong stain-
ing) was initially scored in a discovery set (n = 57). When present in the same slide (adjacent
to tumor) OLFM4 expression was also evaluated in non-dysplastic Barrett’s esophagus
(NDBE). Barrett’s esophagus was defined by metaplasia of the pre-existent squamous epithe-
lium into columnar epithelium containing goblet cells[28]. All OLFM4 stained slides were
reviewed independently by two investigators (LS and FK), blinded to the clinical and pathological
outcome. In case of disagreement, a consensus was reached by review by both investiga-
tors. Specifically, 126 out of 240 cases showed a relatively small difference (1–10%) in scoring,
of which the numbers were averaged. In 32 cases a difference of more than 10% was found,
and a consensus was reached in a consensus meeting.
Statistical analysis
The optimal cut-off value of OLFM4 expression was based on receiver operating characteristic (ROC) curve analysis in advanced EAC, and corresponding Youden index (S1 Fig). Based on this evaluation, low OLFM4 was defined as < 30% expression, otherwise OLFM4 was considered to be high. The interobserver variation for the assessment of OLFM4 staining between the two observers was calculated using the intraclass correlation coefficient. Strength of agreement was categorized as follows: 0.00–0.20, poor; 0.21–0.40, fair; 0.41–0.60, moderate; 0.61–0.80, good; and 0.81–1.00, excellent.

Required sample size was not calculated a priori as no pilot data on OLFM4 in EAC was available to determine an expected effect size and it was also predetermined by study constraints. Differences between the advanced and early EAC cohorts were analyzed using Student’s t test for normal distributions and the Mann–Whitney U test for non-normal distributions of continuous variables, and Pearson’s chi-squared ($\chi^2$) test for categorical variables. Normality of distributions were assessed using the Shapiro-Wilk Test of Normality and by looking at the histogram plot. Correlations between clinicopathological variables and OLFM4 expression were analysed using $\chi^2$- test or Fisher’s exact test. Multivariable logistic regression was used to calculate independent associated factors for LNM in the resection specimen (pN+). Only variables that were statistically significant in univariable analysis were included in multivariable analysis. To investigate whether the association of OLFM4 was different in advanced and early EAC we performed a logistic regression analysis containing all relevant confounders, OLFM4 status, early or advanced EAC and the interaction between OLFM4 status and early or advanced EAC.

Kaplan Meier curves were used to plot the 5-year DFS and OS by OLFM4 status and the distribution was analyzed using the log-rank test. Uni- and multivariable Cox proportional hazard models were applied to calculate the association between OLFM4 and survival. In multivariable analysis all clinical and pathological factors which proved to be prognostic for survival in univariable analysis were included ($p<0.05$). Statistical analysis was performed using SPSS-software (version 22, SPSS IBM inc, Armonk, NY, USA). A $p$-value of $<0.05$ (two-sided) was considered statistically significant. This study was reported according to the Reporting recommendations for tumor marker prognostic studies (REMARK, S1 Table) [29].

Ethical approval
This study was approved by the institutional review board (medical ethical committee) from the Erasmus Medical Center (Rotterdam, The Netherlands).

Results
Patient characteristics
A diagram depicting the flow of patients throughout the study is shown in Fig 1. Out of 240 EAC patients investigated in this study, 196 had advanced EAC (pT2-4) and 44 early EAC (pT1b). Clinicopathological characteristics are listed in Table 1.

Pattern of OLFM4 expression
In total, 240 EAC resection specimens were assessed for OLFM4 expression. The interobserver agreement for OLFM4 assessment was “good” to “excellent” between the two observers with an intraclass correlation co-efficient of 0.871 (95% CI, 0.782–0.918). However, the H-score resulted in a poor interobserver agreement (Cohen’s kappa 0.2) and was disregarded from further analysis. In normal esophageal tissue (without presence of Barrett’s esophagus), OLFM4
expression was absent (S2 Fig). In total, 87 (36.2%) EACs showed high OLFM4 expression and 153 (63.8%) EACs showed low OLFM4 expression (Fig 2). Mostly, expression of OLFM4 was homogeneous, but occasionally, heterogeneous OLFM4 expression was observed, with predominantly high OLFM4 expression towards the lumen and absence of OLFM4 expression towards the invasive front (S3 Fig). Non-dysplastic Barrett’s esophagus (NDBE) showed a similar staining pattern as normal human colon, with cytoplasmic OLFM4 expression in the crypt basis (Fig 2). As in NDBE, OLFM4 expression was noted in the cytoplasm of the EAC cells (Fig 2C).

OLFM4 expression and clinico-pathological characteristics in advanced and early EAC

In advanced EAC, 78 out of 130 (60%) cases with low OLFM4 expression were poorly differentiated, compared to 23 out of 66 (34.8%) EAC with high expression (p = <0.001, Table 2). A similar association between differentiation grade and OLFM4 expression was found in early EAC (9/23 (39%) vs. 2/21 (10%), p = 0.023). Low OLFM4 expression was also associated with presence of pathologically confirmed LNM at the time of resection in EAC (119/153 (78%) vs 51/87 (59%), p = 0.002). In advanced EAC OLFM4 was associated with LNM (113/130 (87%) vs 48/66 (73%), p = 0.014), but not in early EAC (6/23 (26%) vs 3/21 (14%), p = 0.332).

To identify the odds ratio (OR) of clinicopathological characteristics for presence of LNM in EAC, uni- and multivariable logistic regression analysis were performed (Table 3). In multivariable analysis, positive resection margin (OR 7.8, 95% CI, 1.70–35.68, p = 0.008), higher
### Table 1. Patient characteristics.

|                                | All patients (Advanced + Early), | Advanced EAC (pT2-4), | Early EAC (pT1b), | Advanced vs Early |
|--------------------------------|----------------------------------|-----------------------|-------------------|------------------|
|                                | n = 240                          | n = 196               | n = 44            |                  |
| **Age, years (mean [SD])**     | 63 (10)                          | 63 (10)               | 62 (9)            | 0.445§           |
| **Sex (n[%])**                 | Male (82.9)                      | 165 (84.2)            | 34 (77.3)         | 0.271            |
|                                | Female (17.1)                    | 31 (15.8)             | 10 (22.7)         |                  |
| **Surgery (n[%])**             | Transhiatal 150 (62.5)           | 120 (61.2)            | 30 (68.2)         | <0.001           |
|                                | Transthoracal 69 (28.8)          | 67 (34.2)             | 2 (4.5)           |                  |
|                                | Total/Partial Gastric 9 (3.7)    | 8 (4.1)               | 1 (2.3)           |                  |
|                                | Unknown 12 (5.0)                 | 1 (0.5)               | 11 (25)           |                  |
| **Siewert classification,¥(n[%])** | Type 1 114 (47.5)                          | 80 (40.8) | 34 (77.3)         | <0.001           |
|                                | Type 2 125 (52.1)                | 116 (59.2)            | 9 (20.5)          |                  |
| **Tumor size, mm* (mean [SD])** | 46.6 (24.2)                      | 50.6 (23.8)           | 27.4 (15.8)       | <0.001§          |
| **Radicality (n[%])**          | R0 179 (74.6)                    | 135 (68.9)            | 44 (100)          | <0.001           |
|                                | R1 61 (25.4)                     | 61 (31.1)             | 0 (0)             |                  |
| **Grade (n[%])**               | Well / Moderate 128 (53.3)       | 95 (48.5)             | 33 (75)           | 0.001            |
|                                | Poor 112 (46.7)                  | 101 (51.5)            | 11 (25)           |                  |
| **pT (n[%])**                  | pT1b 44 (18.3)                   | 0 (0)                 | 44 (100)          | <0.001           |
|                                | pT2 25 (10.4)                    | 25 (12.8)             | 0 (0)             |                  |
|                                | pT3 168 (70.0)                   | 168 (85.7)            | 0 (0)             |                  |
|                                | pT4 3 (1.3)                      | 3 (1.5)               | 0 (0)             |                  |
| **pN (n[%])**                  | pN0 70 (29.2)                    | 35 (17.9)             | 35 (79.5)         | <0.001           |
|                                | pN1 49 (20.4)                    | 44 (22.4)             | 5 (11.4)          |                  |
|                                | pN2 54 (22.5)                    | 51 (26.0)             | 3 (6.8)           |                  |
|                                | pN3 67 (27.9)                    | 66 (33.7)             | 1 (2.3)           |                  |
| **pN- / pN+ (n[%])**           | pN- 70 (29.2)                    | 35 (17.9)             | 35 (79.5)         | <0.001           |
|                                | pN+ 170 (70.8)                   | 161 (82.1)            | 9 (20.5)          |                  |
| **Total LN (median [IQR])**    | 18 (14–26)                       | 19 (15–27)            | 14 (8–17)         | <0.001*          |
| **LNM (median [IQR])**         | 3 (0–7)                          | 4 (1–8)               | 0 (0–0)           | <0.001*          |
| **Recurrence,¶ n[%]**         | No 98 (40.8)                     | 66 (33.7)             | 32 (72.7)         | <0.001           |
|                                | Yes 140 (59.2)                   | 130 (66.3)            | 10 (22.7)         |                  |
| **Locoregional recurrence,¥ (n[%])** | No 163 (67.9)                          | 123 (62.8) | 40 (90.9)         | <0.001           |
|                                | Yes 76 (31.7)                    | 73 (37.2)             | 3 (6.8)           |                  |
| **Distant recurrence,¶ (n[%])**| No 126 (52.5)                    | 94 (48.0)             | 32 (72.7)         | <0.001           |
|                                | Yes 112 (46.7)                   | 102 (50.2)            | 10 (22.7)         |                  |
| **pN+ and/ or recurrence,¥ (n[%])** | No 49 (20.4)                          | 22 (11.2) | 27 (61.4)         | <0.001           |
|                                | Yes 190 (79.2)                   | 174 (88.8)            | 16 (36.4)         |                  |
| **60 months survival (n[%])**  | Alive 79 (32.9)                  | 46 (23.5)             | 33 (75.0)         | <0.001           |
|                                | Deceased 161 (67.1)              | 150 (76.5)            | 11 (25.0)         |                  |
| **Follow-up time, months (median [IQR])** | 25 (9–64)                          | 19 (8–48) | 38 (47–80)        | <0.001*          |
| **DFS, months (median [IQR])**  | 17 (7–60)                        | 13 (6–35)             | 63 (32–77)        | <0.001*          |
| **OS, months (median [IQR])**   | 25 (9–64)                        | 19 (8–48)             | 64 (47–80)        | <0.001*          |
| **OLFM4 expression,∞ (n[%])**  | Low 153 (63.8)                   | 130 (66.3)            | 23 (59.0)         | 0.080            |

(Continued)
pT-stage (pT3+4, OR 4.0; 95% CI, 1.53–10.29, p = 0.005) and low OLFM4 expression (OR 2.7; 95% CI, 1.16–6.41; p = 0.022) were identified as independent prognostic variables for LNM in advanced EAC. In contrast, no independently prognostic variables were found in early EAC. However, in the combined cohort the interaction test showed no significant difference in strength of the association of OLFM4 with LNM in advanced (OR 2.7; 95% CI, 1.18–6.34; p = 0.019) and early (OR 2.3; 95% CI, 0.47–11.13; p = 0.302) EAC (p = 0.844, Table 4). In other words, this test shows that there is no reason to assume that the association between OLFM4 and presence of LNM is different between both groups.

Table 1. (Continued)

|                      | All patients (Advanced + Early), n = 240 | Advanced EAC (pT2-4), n = 196 | Early EAC (pT1b), n = 44 | Advanced vs Early p-value* |
|----------------------|-----------------------------------------|-------------------------------|--------------------------|---------------------------|
| High                 | 87 (36.2)                               | 66 (33.7)                    | 21 (41.0)                |                           |

*P-values were based on Pearson’s chi-squared test, unless indicated otherwise. All statistical tests were two-sided. SD, standard deviation; R1, positive; R0, negative resection margins; IQR, interquartile range.

§ P-values were based on Student’s t-test.

' P-values were based on Mann-Whitney test.

¥ One sample (early EAC) had unknown data.

* Eight samples (4 advanced, 4 early EAC) had unknown data.

¶ Two samples (early EAC) had unknown data.

∞ Low OLFM4 < 30% and high OLFM4 ≥30% immunohistochemical expression.

https://doi.org/10.1371/journal.pone.0219494.t001

Fig 2. Examples of OLFM4 expression. OLFM4 expression in A, B) normal human colon tissue and C, D) non-dysplastic Barrett’s esophagus overlying OLFM4 negative tumor cells (divided by dotted line). Representative cases of esophageal adenocarcinoma with E, F) high and G, H) low OLFM4 expression (A, C, E, G: hematoxylin–eosin; B, D, F, H: OLFM4).

https://doi.org/10.1371/journal.pone.0219494.g002
OLFM4 expression and prognosis

DFS was significantly better in patients with high OLFM4 expression (for advanced and early EAC cohorts combined, log-rank test, \( p = 0.024 \)). This was confirmed by univariable COX regression analysis (HR 1.5; 95% CI, 1.05–2.15, \( p = 0.027 \)). However, this observation did not hold in multivariable analysis (S2 Table). There was no significant difference in OS between EAC with low vs. high OLFM4 expression. Hence, OLFM4 expression was not prognostic for OS (S3 Table). Kaplan-Meier curves for both DFS and OS according to OLFM4 expression are depicted in S4 Fig. 

Table 2. Distribution of OLFM4 expression according to clinicopathological characteristics in advanced and early EAC.

|                         | All patients (Advanced + Early), n = 240 | Advanced EAC (pT2-4), n = 196 | Early EAC (pT1b), n = 44 |
|-------------------------|------------------------------------------|--------------------------------|--------------------------|
|                         | Low n (%) | High n (%) | p-value* | Low n (%) | High n (%) | p-value* | Low n (%) | High n (%) | p-value* |
| Age                     |           |            |          |           |            |          |           |            |          |
| < 65                    | 81 (52.9) | 46 (52.9)  | 0.992    | 68 (52.3) | 34 (51.5)  | 0.916    | 13 (56.5) | 12 (57.1)  | 0.967    |
| >/= 65                  | 72 (47.1) | 41 (47.1)  | 0.946    | 62 (47.7) | 32 (48.5)  | 0.938    | 10 (43.5) | 9 (42.9)   |          |
| Sex                     |           |            |          |           |            |          |           |            |          |
| Male                    | 129 (84)  | 70 (80.5)  | 0.446    | 111 (85.4)| 54 (81.8)  | 0.518    | 18 (78.3)| 16 (76.2)  | 0.870    |
| Female                  | 24 (15.7) | 17 (19.5)  |           | 19 (14.6)| 12 (18.2)  |           | 5 (21.7) | 5 (23.8)   |          |
| Surgery                 |           |            |          |           |            |          |           |            |          |
| Transhiatal             | 93 (60.8)| 57 (65.5)  | 0.467    | 76 (58.5)| 44 (66.7)  | 0.265    | 17 (73.9)| 13 (61.9)  | 0.393    |
| Other                   | 60 (39.2)| 30 (34.5)  |           | 54 (41.5)| 22 (33.3)  |           | 6 (26.1)| 8 (38.1)   |          |

Siewert Classification, ¥

|                         | All patients (Advanced + Early), n = 240 | Advanced EAC (pT2-4), n = 196 | Early EAC (pT1b), n = 44 |
|-------------------------|------------------------------------------|--------------------------------|--------------------------|
|                         | Low n (%) | High n (%) | p-value* | Low n (%) | High n (%) | p-value* | Low n (%) | High n (%) | p-value* |
| Age                     |           |            |          |           |            |          |           |            |          |
| < 65                    | 75 (49.3) | 39 (44.8)  | 0.501    | 57 (43.8)| 23 (34.8)  | 0.226    | 18 (81.8)| 16 (76.2)  | 0.650    |
| >/= 65                  | 77 (50.7) | 48 (55.2)  |           | 73 (56.2)| 43 (65.2)  |           | 4 (18.2) | 5 (23.8)   |          |
| Tumor Size, ▼           |           |            |          |           |            |          |           |            |          |
| < 5 cm                  | 85 (57.4) | 44 (52.4)  | 0.457    | 66 (52.0)| 28 (43.1)  | 0.243    | 19 (90.5)| 16 (84.2)  | 0.550    |
| >/= 5 cm                | 63 (42.6) | 40 (47.6)  |           | 61 (48.0)| 37 (56.9)  |           | 2 (9.5)  | 3 (15.8)   |          |
| Radicality              |           |            |          |           |            |          |           |            |          |
| R0                      | 115 (75)  | 64 (73.6)  | 0.784    | 92 (70.8)| 43 (65.2)  | 0.422    | 23 (100)| 21 (100)   | NA       |
| R1                      | 38 (24.8)| 23 (26.4)  |           | 38 (29.2)| 23 (34.8)  |           | 0 (0)    | 0 (0)      |          |
| Grade                   |           |            |          |           |            |          |           |            |          |
| Well/ moderate          | 66 (43.1)| 61 (71.3)  | <0.001   | 52 (40.0)| 43 (65.2)  | 0.001    | 14 (60.9)| 19 (90.5)  | 0.023    |
| Poor                    | 87 (56.9)| 25 (28.7)  |           | 78 (60.0)| 23 (34.8)  |           | 9 (39.1)| 2 (9.5)    |          |
| pT                      |           |            |          |           |            |          |           |            |          |
| pT12                    | 38 (24.8)| 31 (35.6)  | 0.076    | 15 (11.5)| 10 (15.2)  | 0.474    | 23 (100)| 21 (100)   | NA       |
| pT34                    | 115 (75)  | 56 (64.4)  |           | 115 (88.5)| 56 (84.8)  |           | 0 (0)    | 0 (0)      |          |
| pN                      |           |            |          |           |            |          |           |            |          |
| pN0                     | 34 (22.2)| 36 (41.4)  | 0.008    | 17 (13.1)| 18 (27.3)  | 0.040    | 17 (73.9)| 18 (85.7)  | 0.380    |
| pN1                     | 33 (21.6)| 16 (18.4)  |           | 29 (22.3)| 15 (22.7)  |           | 4 (17.4)| 1 (4.8)    |          |
| pN2                     | 42 (27.5)| 12 (13.8)  |           | 40 (30.8)| 11 (16.7)  |           | 2 (8.7) | 1 (4.8)    |          |
| pN3                     | 44 (28.8)| 23 (26.4)  |           | 44 (33.8)| 22 (33.3)  |           | 0 (0)    | 1 (4.8)    |          |
| pN- / pN+               |           |            |          |           |            |          |           |            |          |
| pN-                     | 34 (22.2)| 36 (41.4)  | 0.002    | 17 (13.1)| 18 (27.3)  | 0.014    | 17 (73.9)| 18 (85.7)  | 0.332    |
| pN+                     | 119 (78)  | 51 (58.6)  |           | 113 (86.9)| 48 (72.7)  |           | 6 (26.1)| 3 (14.3)   |          |
| Recurrence (loco- regional or distant), ¶        |           |            |          |           |            |          |           |            |          |
| No                      | 54 (35.8)| 44 (50.6)  | 0.025    | 39 (30.0)| 27 (40.9)  | 0.127    | 15 (71.4)| 17 (81.0)  | 0.469    |
| Yes                     | 97 (64.2)| 43 (49.4)  |           | 91 (70.0)| 39 (59.1)  |           | 6 (28.6)| 4 (19.0)   |          |
| pN+ and/ or Recurrence, ¶  |           |            |          |           |            |          |           |            |          |
| No                      | 22 (14.5)| 27 (31.0)  | 0.002    | 10 (7.7) | 12 (18.2)  | 0.028    | 12 (54.5)| 15 (71.4)  | 0.252    |
| Yes                     | 130 (85.5)| 60 (69.0)  |           | 120 (92.3)| 54 (81.8)  |           | 10 (45.5)| 6 (28.6)   |          |

*Pearson’s chi-squared test. NA, not applicable, because all patients with early EAC had negative resection margins (R0) and were per definition staged pT1.

¥ One sample (early EAC) had unknown data.

▼ Eight samples (4 advanced, 4 early EAC) had unknown data

¶ Two samples (early EAC) had unknown data.

https://doi.org/10.1371/journal.pone.0219494.t002
Discussion

This is the first extensive study on OLFM4, an intestinal stem cell marker, in EAC and shows low OLFM4 expression is associated with positive LNM status. Accurate pretreatment staging of patients with early and advanced EAC is important for optimal treatment selection and survival prediction [4–6]. Previous studies have shown that pretreatment staging is frequently inaccurate in EAC [9, 30–33]. In a recent publication on nCRT-naïve patients with standard pre-operative assessment only 35% of patients were preoperatively diagnosed with a correct T- and N-stage [34]. Particularly in patients with early (pT1) EAC, prevalence of LNM is highly variable and to date unpredictable, while positive LNM status is highly predictive for a poor 5-year survival [30, 35].
The significance of OLFM4 in cancer is still controversial. OLFM4 is able to interact with cell surface proteins and known to facilitate cell-cell adhesion [17, 36]. OLFM4 has been attributed oncogenic properties as it was shown to promote tumor growth by acting as an anti-apoptotic protein and by increasing the mitotic activity of cancer cells [37, 38]. On the other hand, reduced OLFM4 expression was significantly associated with poor prognosis in patients with gastric [20], colorectal [23, 39] and breast carcinoma [24] amongst others. In gastric carcinoma OLFM4 was also associated with metastasis [20, 21].

The present study shows low OLFM4 expression was associated with poorly differentiated EAC, this is in concordance with the literature. In fact, in most cancers, a strong association between low OLFM4 and poor tumor differentiation grade was found, including gastric, colon, ovarian and prostate cancer [17, 18, 21, 22, 27, 28]. These findings suggest tumor suppressive properties of OLFM4 and are in line with results found in various functional studies [16, 40, 41]. For example, in gastric cancer cell lines OLFM4 had an inhibitory effect on cell invasion via regulation of focal adhesion kinase (FAK) signaling [41].

Furthermore, low OLFM4 expression, but not poor tumor differentiation, was independently associated with LNM in advanced EAC in the present study. Because LNM status is critical for the choice of treatment in early EAC, the investigation was extended to early EAC and 44 patients with pT1b tumors were separately analyzed. The overall incidence of LNM in the pT1b group (20.5%) was in line with previous reports [29, 30]. Similar as in advanced EAC, loss of OLFM4 was associated with poor differentiation grade, but no association with LNM status was found. However, the interaction test in the combined cohort showed no significant difference in strength of the association of OLFM4 and LNM between the advanced and early
EAC. Therefore, the result in the early EAC might be explained by the small sample size and overall low LNM incidence in this group of patients. Only one previous study studied the role of OLFM4 in early cancer (pT1a and pT1b gastric cancer, n = 105) and concluded that low OLFM4 expression was independently predictive for LNM [21].

Despite the association with LNM, in contrast with results found in other types of cancer, OLFM4 seems to have no effect on clinical outcome. However, there are some important differences between the present study and the aforementioned previous studies on OLFM4 in other cancers. In the present study, only patients with at least 12 lymph nodes resected and identified were included, in order to reduce the percentage of patients with falsely negative pN0 [42]. Although others may have included more cases, these studies were frequently based on patients with various tumor stages and mostly used tissue micro-arrays (TMAs) instead of whole tissue slides. In addition, different methods for scoring OLFM4 IHC were applied making comparison of results difficult [18–23]. Importantly, TMAs may not accurately demonstrate tumor heterogeneity, which was observed in our study occasionally. In addition, whole tissue slides allow for simultaneous analyses of adjacent non-tumorous tissue and Barrett’s esophagus. It would be very interesting to investigate OLFM4 expression in low-grade and high-grade dysplasia. However, in our samples, BE, with or without dysplasia, was present in only a limited number of cases. Therefore, investigation of OLFM4 expression patterns during neoplastic progression would require a separate study design using well defined sample criteria.

There are also some limitations to the present study. Specifically, all patients were from one academic center. Also, patients were treated with surgery alone, while current guidelines recommend nCRT prior to surgery for advanced EAC. However, additional treatment prior to surgery might influence OLFM4 expression and survival, hence it was decided to use a nCRT-naïve patient cohort.

In conclusion, the present study shows that low OLFM4 expression was independently associated with LNM in EAC and hence might prove useful as a new biomarker. Improved prediction of LNM presence could benefit decision making in treatment of EAC patients. This is particularly important in early EAC where overtreatment can be avoided by endoscopic submucosal resection. More research is required to investigate whether OLFM4 is indeed biologically and clinically relevant in both advanced and early EAC.

Supporting information

S1 Fig. Receiver operating characteristics–curve for OLFM4 expression, according to the % of positive tumor cells (cytoplasm), and corresponding Youden index. (DOCX)

S2 Fig. OLFM4 expression in normal esophageal tissue. A, B) Normal esophageal tissue is negative for OLFM4. C, D) Magnification of A. Only neutrophils are OLFM4 positive (brown dots indicated by arrows) and can be used as positive internal control (A, B: hematoxylin-eosin; C, D: OLFM4). (DOCX)

S3 Fig. Two examples of cases with heterogeneous OLFM4 expression. In A, B) tumor invading into the muscularis propria and adventitia can be seen. While the tumor in the mucosa, submucosa and muscularis propria is positive for OLFM4, two complete OLFM4 negative clones invading the surrounding fatty tissue can be seen (dotted line). C, D) Magnification of A, B, E, F) A well differentiated tumor with several OLFM4 positive tumor foci towards the lumen (squamous epithelium) and complete absence (below dotted line) of OLFM4
expression in tumor foci towards the invasive front. G, H) Magnification of E, F (A, C, E, G: hematoxylin–eosin; B, D, F, H: OLFM4).

S4 Fig. Kaplan-Meier curves for disease free survival (DFS, left) and overall survival (OS, right) according to OLFM4 expression. DFS and OS of both cohorts (upper two), patients with advanced (middle two) and patients with early (lower two) esophageal adenocarcinoma. Overall, DFS is better in patients with tumors with high OLFM4 expression, although this difference is only significant when both cohorts are combined (p = 0.024, log-rank test). There is no significant difference in OS between EAC with low vs. high OLFM4 expression (log-rank test).

S1 Table. The REMARK checklist.

S2 Table. Cox regression analysis to evaluate the risk for recurrence (DFS). Uni- and multivariable Cox regression analysis was performed to investigate the independent association between disease free survival (DFS) and clinicopathological characteristics, only variables significant in univariable analysis were included in multivariable analysis. Hence, no multivariable analysis for early esophageal adenocarcinoma (EAC) was performed. HR, hazard ratio; CI, confidence interval; ref., reference; NA = not applicable, because all patients with early EAC had negative resection margins (R0) and were per definition staged pT1. ▼ One sample (early EAC) had unknown data. ▼ Eight samples (4 advanced, 4 early EAC) had unknown data.

S3 Table. COX regression analysis for OS. Uni- and multivariable Cox regression analysis was performed to investigate the independent association between overall survival (OS) and clinicopathological characteristics, only variables significant in univariable analysis were included in multivariable analysis. Hence, no multivariable analysis for early esophageal adenocarcinoma (EAC) was performed. HR, hazard ratio; CI, confidence interval; ref., reference; NA = not applicable, because all patients with early EAC had negative resection margins (R0) and were per definition staged pT1. ▼ One sample (early EAC) had unknown data. ▼ Eight samples (4 advanced, 4 early EAC) had unknown data.

Author Contributions

Conceptualization: Lucia Suzuki, Annieke W. Gotink, Hans Stoop, Daan Nieboer, Manon C. W. Spaander, Jan J. B. van Lanschot, Bas P. L. van Wijnhoven, Arjun D. Koch, Leendert H. J. Looijenga.

Formal analysis: Lucia Suzuki, Daan Nieboer.

Funding acquisition: Katharina Biermann.

Investigation: Lucia Suzuki, Fiebo J. C. ten Kate, Annieke W. Gotink, Hans Stoop.

Methodology: Lucia Suzuki.

Project administration: Leendert H. J. Looijenga, Katharina Biermann.

Resources: Hans Stoop, Manon C. W. Spaander, Jan J. B. van Lanschot, Bas P. L. van Wijnhoven, Arjun D. Koch, Marco J. Bruno, Leendert H. J. Looijenga, Katharina Biermann.
Supervision: Leendert H. J. Looijenga, Katharina Biermann.

Visualization: Lucia Suzuki.

Writing – original draft: Lucia Suzuki, Leendert H. J. Looijenga, Katharina Biermann.

Writing – review & editing: Lucia Suzuki, Fiebo J. C. ten Kate, Annieke W. Gotink, Hans Stoop, Michail Doukas, Daan Nieboer, Manon C. W. Spaander, Jan J. B. van Lanschot, Bas P. L. van Wijnhoven, Arjun D. Koch, Marco J. Bruno, Leendert H. J. Looijenga, Katharina Biermann.

References

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49 (6):1374–403. https://doi.org/10.1016/j.ejca.2012.12.027 PMID: 23485231

2. Abnet CC, Arnold M, Wei WQ. Epidemiology of Esophageal Squamous Cell Carcinoma. Gastroenterology. 2018; 154(2):360–73. https://doi.org/10.1053/j.gastro.2017.08.023 PMID: 28623862

3. Coleman HG, Xie SH, Lagergren J. The Epidemiology of Esophageal Adenocarcinoma. Gastroenterology. 2018; 154(2):390–405. https://doi.org/10.1053/j.gastro.2017.07.046 PMID: 28780073

4. Sobin L, Gospodarowicz M, Wittekind C, editors. TNM Classification of Malignant Tumours. 7th ed2009.

5. Akutsu Y, Matsubara H. The significance of lymph node status as a prognostic factor for esophageal cancer. Surg Today. 2011; 41(9):1190–5. https://doi.org/10.1007/s00595-011-4542-y PMID: 21874413

6. Wang WP, He SL, Yang YS, Chen LQ. Strategies of nodal staging of the TNM system for esophageal cancer. Ann Transl Med. 2018; 6(4):77. https://doi.org/10.21037/atm.2017.12.17 PMID: 29666800

7. Bergeron EJ, Lin J, Chang AC, Orringer MB, Reddy RM. Endoscopic ultrasound is inadequate to determine which T1/T2 esophageal tumors are candidates for endoluminal therapies. J Thorac Cardiovasc Surg. 2014; 147(2):765–71: Discussion 71–3. https://doi.org/10.1016/j.jtcvs.2013.10.003 PMID: 24314788

8. Betancourt Cuellar SL, Sabloff B, Carter BW, Benveniste MF, Correa AM, Maru DM, et al. Early clinical esophageal adenocarcinoma (ct1): Utility of CT in regional nodal metastasis detection and can the clinical accuracy be improved? Eur J Radiol. 2017; 88:56–60. https://doi.org/10.1016/j.ejrad.2017.01.001 PMID: 26189209

9. Grotenhuis BA, Wijnhoven BP, Poley JW, Hermans JJ, Biermann K, Spaander MC, et al. Preoperative assessment of tumor location and station-specific lymph node status in patients with adenocarcinoma of the gastroesophageal junction. World J Surg. 2013; 37(1):147–55. https://doi.org/10.1007/s00268-012-1804-9 PMID: 23015224

10. Snyder DA, Rivers AM, Yokoe H, Menco BP, Anholt RR. Olfactomedin: purification, characterization, and localization of a novel olfactory glycoprotein. Biochemistry. 1991; 30(38):9143–53. https://doi.org/10.1021/bi00102a004 PMID: 18928225

11. Zhang J, Liu WL, Tang DC, Chen L, Wang M, Pack SD, et al. Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene. 2002; 283(1–2):83–93. PMID: 11867215

12. van der Flier LG, Haegerbart A, Stange DE, van de Wetering M, Clevers H. OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. Gastroenterology. 2009; 137(1):15–7. https://doi.org/10.1053/j.gastro.2009.05.035 PMID: 19450592

13. Jang BG, Lee BL, Kim WH. Intestinal Stem Cell Markers in the Intestinal Metaplasia of Stomach and Barrett’s Esophagus. PLoS One. 2015; 10(5):e0127300. https://doi.org/10.1371/journal.pone.0127300 PMID: 25996368

14. Chin KL, Aerbajina W, Zhu J, Drew L, Chen L, Liu W, et al. The regulation of OLFM4 expression in myeloid precursor cells relies on NF-kappaB transcription factor. Br J Haematol. 2008; 143(3):421–32. https://doi.org/10.1111/j.1365-2457.2008.06796.x PMID: 18764866

15. Kim KK, Park KS, Song SB, Kim KE. Up regulation of GW112 Gene by NF kappaB promotes an antiapoptotic property in gastric cancer cells. Mol Carcinog. 2010; 49(3):259–70. https://doi.org/10.1002/mc.20596 PMID: 19908244

16. Liu W, Li H, Hong SH, Piszczech GP, Chen W, Rodgers GP. Olfactomedin 4 deletion induces colon adenocarcinoma in ApcMin/+ mice. Oncogene. 2016; 35(40):5237–47. https://doi.org/10.1038/onc.2016.58 PMID: 26973250
17. Liu W, Chen L, Zhu J, Rodgers GP. The glycoprotein hGC-1 binds to cadherin and lectins. Exp Cell Res. 2006; 312(10):1785–97. https://doi.org/10.1016/j.yexcr.2006.02.011 PMID: 16566923

18. Jang BG, Lee BL, Kim WH. Olfactomedin-related proteins 4 (OLFM4) expression is involved in early gastric carcinogenesis and of prognostic significance in advanced gastric cancer. Virchows Arch. 2015; 467(3):285–94. https://doi.org/10.1007/s00428-015-1793-9 PMID: 26070873

19. Liu W, Zhu J, Cao L, Rodgers GP. Expression of hGC-1 is correlated with differentiation of gastric carcinoma. Histopathology. 2007; 51(2):157–65. https://doi.org/10.1111/j.1365-2559.2007.02763.x PMID: 17650212

20. Luo Z, Zhang Q, Zhao Z, Li B, Chen J, Wang Y. OLFM4 is associated with lymph node metastasis and poor prognosis in patients with gastric cancer. J Cancer Res Clin Oncol. 2011; 137(11):1713–20. https://doi.org/10.1007/s00432-011-1042-9 PMID: 21904905

21. Zhao J, Shu P, Duan F, Wang X, Min L, Shen Z, et al. Loss of OLFM4 promotes tumor migration through inducing interleukin-8 expression and predicts lymph node metastasis in early gastric cancer. Oncogenesis. 2016; 5(6):e234. https://doi.org/10.1038/oncsis.2016.42 PMID: 27294866

22. Li H, Rodriguez-Canales J, Liu W, Zhu J, Hanson JC, Pack S, et al. Deletion of the olfactomedin 4 gene is associated with progression of human prostate cancer. Am J Pathol. 2013; 183(4):1329–38. https://doi.org/10.1016/j.ajpath.2013.06.028 PMID: 24070418

23. Liu W, Liu Y, Zhu J, Wright E, Ding I, Rodgers GP. Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma. Clin Cancer Res. 2008; 14(4):1041–9. https://doi.org/10.1158/1078-0432.CCR-07-2276 PMID: 18281536

24. Xiong B, Lei X, Zhang L, Fu J. The clinical significance and biological function of olfactomedin 4 in triple negative breast cancer. Biomedicine & Pharmacotherapy. 2017; 86:67–73.

25. Duan C, Liu X, Liang S, Yang Z, Xia M, Wang L, et al. Oestrogen receptor-mediated expression of Olfactomedin 4 regulates the progression of endometrial adenocarcinoma. J Cell Mol Med. 2014; 18(5):863–74. https://doi.org/10.1111/jcmm.12323 PMID: 24492525

26. Edge SB BD, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual ( 7th ed). New York, NY: Springer; 2010.

27. Bertero L, Massa F, Metovic J, Zanetti R, Castellano I, Ricardi U, et al. Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why? Virchows Arch. 2018; 472(4):519–31. https://doi.org/10.1007/s00428-017-2276-y PMID: 29209757

28. Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of G. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. Am J Gastroenterol. 2016; 111(1):30–50; quiz 1. https://doi.org/10.1038/ajg.2015.322 PMID: 26526079

29. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med. 2012; 10:51. https://doi.org/10.1186/1741-7015-10-51 PMID: 22642691

30. Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, et al. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol. 2014; 9(8):1202–6. https://doi.org/10.1097/JTO.0000000000000222 PMID: 25157774

31. Khanna LG, Gress FG. Preoperative evaluation of oesophageal adenocarcinoma. Best Pract Res Clin Gastroenterol. 2015; 29(1):179–91. https://doi.org/10.1016/j.bpg.2014.12.005 PMID: 25743465

32. Pech O, Gunter E, Dusemund F, Origer J, Lorenz D, Ell C. Accuracy of endoscopic ultrasound in preoperative staging of esophageal cancer: results from a referral center for early esophageal cancer. Endoscopy. 2010; 42(6):456–61. https://doi.org/10.1055/s-0029-1244022 PMID: 20363858

33. Tekola BD, Sauer BG, Wang AY, White GE, Shami VM. Accuracy of endoscopic ultrasound in the diagnosis of T2N0 esophageal cancer. J Gastrointest Cancer. 2014; 45(3):342–6. https://doi.org/10.1007/s12029-014-9616-9 PMID: 24788081

34. Winiker M, Mantziari S, Figueiredo SG, Demartines N, Allempenn P, Schafer M. Accuracy of preoperative staging for a priori resectable esophageal cancer. Dis Esophagus. 2018; 31(1):1–6.

35. Dubecz A, Kern M, Solyomini S, Schweigert M, Stein HJ. Predictors of Lymph Node Metastasis in Surgically Resected T1 Esophageal Cancer. Ann Thorac Surg. 2015; 99(6):1789–85; discussion 86. https://doi.org/10.1016/j.athoracsur.2015.02.112 PMID: 25929888

36. Grover PK, Hardingham JE, Cummins AG. Stem cell marker olfactomedin 4: critical appraisal of its characteristics and role in tumorigenesis. Cancer Metastasis Rev. 2010; 29(4):761–75. https://doi.org/10.1007/s10555-010-9262-z PMID: 20878207

37. Kobayashi D, Koshida S, Moriari R, Tsuji N, Watanabe N. Olfactomedin 4 promotes S-phase transition in proliferation of pancreatic cancer cells. Cancer Sci. 2007; 98(3):334–40. https://doi.org/10.1111/j.1349-7006.2007.00397.x PMID: 17270022
38. Zhang X, Huang Q, Yang Z, Li Y, Li CY. GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res. 2004; 64(7):2474–81. PMID: 15059901

39. Seko N, Oue N, Noguchi T, Sentani K, Sakamoto N, Hinoi T, et al. Olfactomedin 4 (GW112, hGC-1) is an independent prognostic marker for survival in patients with colorectal cancer. Exp Ther Med. 2010; 1 (1):73–8. https://doi.org/10.3892/etm_00000013 PMID: 23136596

40. Chen L, Li H, Liu W, Zhu J, Zhao X, Wright E, et al. Olfactomedin 4 suppresses prostate cancer cell growth and metastasis via negative interaction with cathepsin D and SDF-1. Carcinogenesis. 2011; 32 (7):986–94. https://doi.org/10.1093/carcin/bgr065 PMID: 21470957

41. Guo LL, He ZC, Yang CQ, Qiao PT, Yin GL. Epigenetic silencing of olfactomedin-4 enhances gastric cancer cell invasion via activation of focal adhesion kinase signaling. BMB Rep. 2015; 48(11):630–5. https://doi.org/10.5483/BMBRep.2015.48.11.130 PMID: 26303970

42. Dutkowski P, Hommel G, Bottger T, Schlick T, Junginger T. How many lymph nodes are needed for an accurate pN classification in esophageal cancer? Evidence for a new threshold value. Hepatogastroenterology. 2002; 49(43):176–80. PMID: 11941947